Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.30 USD

1.30
397,986

+0.01 (0.78%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.30 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PRA Health (PRAH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Solid Clinical Research revenues drove PRA Health's (PRAH) Q4 results.

Zacks Equity Research

HMS Holdings (HMSY) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

HMS Holdings' (HMSY) fourth-quarter earnings benefit from higher revenues at Analytical Services unit and strong 2020 outlook.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.

Zacks Equity Research

Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.

Zacks Equity Research

Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive

by Zacks Equity Research

Masimo (MASI) sees expansion in gross and operating margin in Q4.

Zacks Equity Research

Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

We are upbeat about the strong year-over-year revenue growth in the Clinical Solutions segment of Syneos Health (SYNH) in Q4.

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Henry Schein (HSIC) registers solid performance by each of its key operating businesses in Q4.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx

Zacks Equity Research

Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

Zacks Equity Research

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4

by Zacks Equity Research

Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.

Zacks Equity Research

Medtronic (MDT) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Medtronic (MDT) demonstrates better-than-expected Q3 performances at CER, backed by growth in all major business segments and geographies.

Nalak Das headshot

Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks

by Nalak Das

President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.

Zacks Equity Research

Change Healthcare (CHNG) Q3 Earnings Top Estimates, Down Y/Y

by Zacks Equity Research

Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.

Zacks Equity Research

DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Bio-Rad's (BIO) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.

Zacks Equity Research

LabCorp's (LH) Q4 Earnings Beat Estimates, Margins Rise

by Zacks Equity Research

LabCorp (LH) registered year-over-year growth in operating segments in Q4.

Zacks Equity Research

Ares Management (ARES) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ares Management (ARES) delivered earnings and revenue surprises of 34.00% and 14.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve

by Zacks Equity Research

CVS Health (CVS) registers strong growth in Pharmacy Services, benefiting from the upside in specialty services.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

by Zacks Equity Research

Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.

Tirthankar Chakraborty headshot

Virus or No Virus, Investing Case in US Stocks Looks Solid!

by Tirthankar Chakraborty

U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging markets during chaotic times.

Zacks Equity Research

Radware (RDWR) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Radware (RDWR) delivered earnings and revenue surprises of -4.17% and -0.22%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss

by Zacks Equity Research

DaVita (DVA) gains from dialysis services in the United States in Q4.